---
document_datetime: 2023-09-21 17:14:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/paxene-epar-procedural-steps-taken-authorisation_en.pdf
document_name: paxene-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4441949
conversion_datetime: 2025-12-14 14:27:36.290709
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Norton Healthcare Limited submitted on 29 October 1997 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Paxene, through  the  centralised  procedure.  This  medicinal  product  falls  within  the  scope  of  Part  B  of  the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993, as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

M. Teeling

Co-Rapporteur:

B. Odlind

## Licensing status:

The product was not authorised in any country inside or outside the EU at the time of submission of the application. It has been reported that the applicant has received tentative approval from the FDA for its NDA for Paxene, but that in view of Taxol's orphan drug exclusivity for a related indication, the application for Paxene may not be finally approved until 4 th August 2004.

## 2. Steps taken for the assessment of the product

- The procedure started on 21 November 1997.
- The Rapporteur's first assessment report was circulated to all CPMP  Members on 6 February 1998.
- The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 30 January 1998.
- During  the  meeting  on  24-25  March  1998  the  CPMP  agreed  on  the  consolidated  list  of questions  to  be  sent  to  the  applicant.  The  final  consolidated  list  of  questions  was  sent  to  the applicant on 25 March 1998.
- The applicant submitted the responses to the consolidated list of questions on 25 September 1998 .
- The Rapporteur circulated the joint response assessment report on the applicant's responses to the list of questions to all CPMP Members on 23 November 1998.
- During the meeting on 15-17 December 1998 the CPMP agreed on a list of outstanding issues to be  sent  to  the  applicant.  The  final  list  of  outstanding  issues  was  sent  to  the  applicant  on 18 December 1998.
- The applicant  submitted  further  responses  to  questions  related  to  pharmaceutical  and  clinical issues on 11 January 1999.
- The Rapporteur circulated the response assessment report on the applicant's responses to the list of outstanding issues on 15 January 1999.

Medicinal product no longer authorised

- During the meeting on 26-28 January 1999 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee  issued  a  positive  Opinion  for  granting  a Marketing Authorisation to Paxene on 27 January 1999.
- The  CPMP  Opinion  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission on 4 March 1999.
- In  a  letter  dated  23  March  1999,  the  European  Commission  informed  the  EMEA  that  the procedure for the granting of the Marketing Authorisation was suspended and the Commision requested the CPMP to provide further clarification.
- On 22 April 1999 the CPMP provided satisfactory clarification to the Commission Services
- The  suspension  of  the  decision  making  process  was  therefore  lifted  and  subsequently  a favourable Opinion was given by the Standing Committee.
- The European Commission adopted the Decision on 19 July 1999.